Sansure Biotech 圣湘生物
22 significant filings since 30 May 2026: 3 on court enforcement, 2 on regulatory inquiry and 9 on buyback, and 4 other kinds. The latest, on 27 Aug 2026: 圣湘生物科技股份有限公司关于实施回购股份注销暨股份变动公告.
自 30 May 2026 起有 22 份重大公告：court enforcement 3 份、regulatory inquiry 2 份、buyback 9 份，另有 4 类。最新一份（27 Aug 2026）：圣湘生物科技股份有限公司关于实施回购股份注销暨股份变动公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳,雷瑞 | Unrated | 11 May 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。